Last updated on September 2017

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children


Brief description of study

This will be an open-label, randomized, multicenter, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency.

Clinical Study Identifier: NCT02968004

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Paul saenger, MD, PhD

Paul Saenger
Mineola, NY United States
  Connect »

Nora Zuluaga

Hospital Universitario San Vicente de Paul
Medellin, Colombia
  Connect »

Veronica Abad, MD.

Hospital Pablo Tobon Uribe
Medellín, Colombia
  Connect »

Jeisson Arevalo

Fundaci n CardioInfantil
Bogotá, Colombia
  Connect »